The HTRA1 Knockout 143B Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 143B human osteosarcoma cell line. This product provides a heterogeneous pool of HTRA1-disrupted cells generated by CRISPR/Cas9-mediated gene targeting at the HTRA1 locus, resulting in loss of HTRA1 serine protease expression. The polyclonal format captures a diverse range of editing outcomes without clonal selection, offering a physiologically relevant representation of HTRA1 deficiency within the tumor cell context.
The 143B cell line is a well-established human osteosarcoma model originally derived from a primary tumor. These cells exhibit highly aggressive behavior, including rapid proliferation, robust tumorigenicity, and prominent metastatic potential in vivo. 143B cells are widely employed to investigate mechanisms of bone cancer progression, metastasis, and therapeutic response. Their mesenchymal origin and active extracellular matrix remodeling pathways make them particularly suitable for studying the interplay between proteolytic enzymes and the tumor microenvironment.
HTRA1 encodes a secreted serine protease that functions as a critical modulator of TGF-?? signaling and extracellular matrix (ECM) dynamics. HTRA1 proteolytically cleaves and inactivates TGF-?? family members, including TGF-??1 and bone morphogenetic proteins (BMPs), thereby attenuating downstream SMAD2/3 and SMAD4 transcriptional programs. Beyond TGF-?? regulation, HTRA1 digests ECM components such as fibronectin and proteoglycans, and interacts with amyloid precursor protein. Its activity is itself regulated by cellular stress and TGF-??/BMP signaling, forming a feedback network that governs cell adhesion, migration, and apoptosis. Representative pathway components impacted by HTRA1 loss include ??-catenin, integrins, and fibronectin, linking it to both TGF-?? and Wnt signaling axes.
In osteosarcoma cells, loss of HTRA1 function is postulated to unleash TGF-??-driven pro-tumorigenic programs. Removal of HTRA1-mediated proteolytic restraint on TGF-?? ligands can amplify SMAD-dependent signaling, promoting epithelial-to-mesenchymal transition (EMT)-like phenotypes, enhanced cell motility, and invasive capacity. The 143B osteosarcoma background, already characterized by high metastatic propensity, provides a stringent model to dissect how HTRA1 deficiency cooperates with intrinsic oncogenic pathways to accelerate tumor progression. This polyclonal knockout population thus enables researchers to interrogate the functional consequences of HTRA1 disruption within a clinically relevant bone cancer context.
The HTRA1 Knockout 143B Polyclonal Cells are optimally suited for investigating HTRA1-dependent regulation of osteosarcoma metastasis, TGF-?? pathway activation, and ECM remodeling. Compatible assays include western blotting and RT-qPCR to confirm HTRA1 loss and monitor downstream targets such as phospho-SMAD2/3, fibronectin, and ??-catenin. Migration and invasion assays, apoptosis quantification, and immunofluorescence staining for cytoskeletal and adhesion markers allow detailed phenotypic characterization. Co-immunoprecipitation can probe altered protein interactions within the TGF-??/BMP axis, supporting tumor suppression studies and preclinical evaluation of targeted therapeutics. For further technical details, please contact Ascent Research.
